Edgewise Therapeutics Inc (NASDAQ: EWTX)’s stock price has soared by 0.66 in relation to previous closing price of 25.85. Nevertheless, the company has seen a loss of -9.31% in its stock price over the last five trading days. seekingalpha.com reported 2024-12-31 that Company achieved positive phase 2 CANYON study results for sevasemten in Becker Muscular Dystrophy, boosting long-term investment potential. Key catalysts include FDA and EMA meetings, GRAND CANYON study recruitment completion, and phase 2 CANYON data publication, all expected to likely enhance shareholder value. The pipeline extends beyond BMD, with sevasemten in phase 2 trials for Duchenne Muscular Dystrophy and EDG-7500 targeting Hypertrophic Cardiomyopathy, offering multiple growth opportunities.
Is It Worth Investing in Edgewise Therapeutics Inc (NASDAQ: EWTX) Right Now?
Company’s 36-month beta value is 0.22.Analysts have differing opinions on the stock, with 4 analysts rating it as a “buy,” 3 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for EWTX is 62.40M, and currently, short sellers hold a 11.31% ratio of that floaft. The average trading volume of EWTX on February 14, 2025 was 853.60K shares.
EWTX’s Market Performance
EWTX stock saw a decrease of -9.31% in the past week, with a monthly decline of -5.45% and a quarterly a decrease of -26.35%. The volatility ratio for the week is 5.32%, and the volatility levels for the last 30 days are 6.02% for Edgewise Therapeutics Inc (EWTX). The simple moving average for the past 20 days is -5.39% for EWTX’s stock, with a 6.88% simple moving average for the past 200 days.
Analysts’ Opinion of EWTX
Many brokerage firms have already submitted their reports for EWTX stocks, with Stifel repeating the rating for EWTX by listing it as a “Hold.” The predicted price for EWTX in the upcoming period, according to Stifel is $30 based on the research report published on January 22, 2025 of the current year 2025.
Evercore ISI, on the other hand, stated in their research note that they expect to see EWTX reach a price target of $45. The rating they have provided for EWTX stocks is “Outperform” according to the report published on November 22nd, 2024.
Piper Sandler gave a rating of “Overweight” to EWTX, setting the target price at $48 in the report published on March 07th of the previous year.
EWTX Trading at -8.29% from the 50-Day Moving Average
After a stumble in the market that brought EWTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -31.74% of loss for the given period.
Volatility was left at 6.02%, however, over the last 30 days, the volatility rate increased by 5.32%, as shares sank -7.73% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -21.15% lower at present.
During the last 5 trading sessions, EWTX fell by -9.31%, which changed the moving average for the period of 200-days by +60.92% in comparison to the 20-day moving average, which settled at $27.50. In addition, Edgewise Therapeutics Inc saw -2.55% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at EWTX starting from Russell Alan J, who sale 8,015 shares at the price of $30.02 back on Feb 05 ’25. After this action, Russell Alan J now owns 14,863 shares of Edgewise Therapeutics Inc, valued at $240,623 using the latest closing price.
Russell Alan J, the Chief Scientific Officer of Edgewise Therapeutics Inc, sale 1,200 shares at $30.13 during a trade that took place back on Feb 06 ’25, which means that Russell Alan J is holding 14,863 shares at $36,153 based on the most recent closing price.
Stock Fundamentals for EWTX
Current profitability levels for the company are sitting at:
- -65.34 for the present operating margin
- 0.29 for the gross margin
The net margin for Edgewise Therapeutics Inc stands at -55.19. The total capital return value is set at -0.3. Equity return is now at value -31.90, with -30.22 for asset returns.
Based on Edgewise Therapeutics Inc (EWTX), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -24.53. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is -47.36.
Currently, EBITDA for the company is -112.81 million with net debt to EBITDA at 0.28. When we switch over and look at the enterprise to sales, we see a ratio of 1076.12. The liquidity ratio also appears to be rather interesting for investors as it stands at 26.35.
Conclusion
In a nutshell, Edgewise Therapeutics Inc (EWTX) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
